Список проголосовавших за комментарий "Vertex Pharm follow up Price: 54.09 Change: -2.91 <br/> Shares ticked higher following a tweet from a popular biotech blogger that said a waterfall plot of individual patient response at the 600mg looked strong, however, shares have sinced traded lower on an update regarding sweat chloride reduction. It was reported that the presenter said one should not expect a tight correlation between sweat chloride reduction and lung function (FEV1). Reduction in sweat chloride is a co-primary endpoint of the Phase 2 study."